Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -96.49% is 49% above its 5-year average of -190.40%, near the high end of its 5-year range (-353.96%–-96.40%).
11.68% above its 12-month average of -109.25%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -29.05%.
RETURN ON ASSETS (ROA)
-96.49%
RETURN ON ASSETS (ROA) AVG TTM
-109.25%
RETURN ON ASSETS (ROA) AVG 3Y
-126.41%
RETURN ON ASSETS (ROA) AVG 5Y
-190.40%
RETURN ON ASSETS (ROA) AVG 10Y
-186.49%
RETURN ON ASSETS (ROA) AVG 15Y
-147.02%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+11.68%
CURRENT VS 3Y AVG
+23.67%
CURRENT VS 5Y AVG
+49.32%
CURRENT VS 10Y AVG
+48.26%
CURRENT VS 15Y AVG
+34.37%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-30.08%
median of 663 covered companies
CURRENT VS SECTOR MEDIAN
-220.78%
vs the sector median at left
TuHURA Biosciences, Inc.
Market Cap
$121.00M
Return on Assets (ROA)
-96.49%
TTM Avg
-109.25%
3Y Avg
-126.41%
5Y Avg
-190.40%
Market Cap
$122.59M
Return on Assets (ROA)
-1.70%
TTM Avg
-35.34%
3Y Avg
-51.03%
5Y Avg
-36.99%
Market Cap
$122.13M
Return on Assets (ROA)
-31.33%
TTM Avg
-56.73%
3Y Avg
-59.49%
5Y Avg
-64.55%
Market Cap
$118.80M
Return on Assets (ROA)
-53.26%
TTM Avg
-24.98%
3Y Avg
-43.10%
5Y Avg
-143.56%
Market Cap
$118.02M
Return on Assets (ROA)
-167.64%
TTM Avg
-183.95%
3Y Avg
-119.46%
5Y Avg
-95.34%
Market Cap
$124.91M
Return on Assets (ROA)
-68.74%
TTM Avg
-454.56%
3Y Avg
-368.82%
5Y Avg
-586.69%
Market Cap
$117.53M
Return on Assets (ROA)
-72.42%
TTM Avg
-66.03%
3Y Avg
-45.57%
5Y Avg
-48.77%
Market Cap
$116.36M
Return on Assets (ROA)
-128.96%
TTM Avg
-127.49%
3Y Avg
-112.64%
5Y Avg
-129.28%
Market Cap
$115.99M
Return on Assets (ROA)
-134.18%
TTM Avg
-145.83%
3Y Avg
-164.39%
5Y Avg
-180.40%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TuHURA Biosciences, Inc. (HURA) | $121.00M | -96.49% | -109.25% | -126.41% | -190.40% |
| enGene Holdings Inc. (ENGN)vs › | $122.59M | -1.70% | -35.34% | -51.03% | -36.99% |
| Cibus, Inc. (CBUS)vs › | $122.13M | -31.33% | -56.73% | -59.49% | -64.55% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.80M | -53.26% | -24.98% | -43.10% | -143.56% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.02M | -167.64% | -183.95% | -119.46% | -95.34% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $124.91M | -68.74% | -454.56% | -368.82% | -586.69% |
| Caribou Biosciences, Inc. (CRBU)vs › | $117.53M | -72.42% | -66.03% | -45.57% | -48.77% |
| Genelux Corporation (GNLX)vs › | $116.36M | -128.96% | -127.49% | -112.64% | -129.28% |
| Lucid Diagnostics Inc. (LUCD)vs › | $115.99M | -134.18% | -145.83% | -164.39% | -180.40% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $114.74M | -31.75% | -34.00% | -32.33% | -29.29% |
ROA
-96.5%
ROE
-165.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -109.90% |
| 2024-12-31 | -108.59% |
| 2023-12-31 | -190.75% |
| 2022-12-31 | -96.40% |
| 2021-12-31 | -353.96% |
| 2021-06-30 | -282.79% |
| 2020-06-30 | -310.62% |
| 2019-06-30 | -199.35% |
| 2018-06-30 | -157.44% |
| 2017-06-30 | -102.16% |
| 2016-06-30 | -139.48% |
| 2015-06-30 | -168.82% |
| 2013-12-31 | -191.97% |
| 2012-06-30 | 0.00% |
| 2011-06-30 | 0.00% |
| 2010-06-30 | 0.00% |
